DUROLANE®

Order DUROLANE® Online

DUROLANE® is a single-injection NASHA (Non-Animal Stabilized Hyaluronic Acid) viscosupplement formulated as a 60 mg/3 mL intra-articular gel for the symptomatic treatment of osteoarthritis. Indications vary by country; in the US, DUROLANE® is FDA-approved for knee osteoarthritis, while non-US labeling may cover additional joints depending on the market [2][3]. Licensed practitioners can buy DUROLANE® online through Medical Spa Rx, with secure checkout and both individual and bulk ordering options available. Order DUROLANE® below and explore the full range of orthopedic injection options on the platform.

Why Practitioners Choose DUROLANE® Over Other Viscosupplements

DUROLANE® holds a distinctive position among single-injection viscosupplements for two reasons that directly affect clinical planning and patient selection.

The first is its indication breadth by market. In the United States, DUROLANE® carries FDA Premarket Approval for knee osteoarthritis in patients who have not responded adequately to conservative therapy or simple analgesics [2][3]. Non-US labeling may support use in additional joints depending on the applicable regional IFU — giving practitioners in those markets flexibility that most single-injection alternatives do not offer [4].

The second is the clinical durability of its NASHA-stabilized formulation. A single 60 mg injection is supported by a systematic evidence review showing pain relief lasting up to 26 weeks in some patients, with a pivotal study demonstrating non-inferiority to a five-injection hyaluronic acid regimen [1]. DUROLANE® also carries an established reimbursement pathway through HCPCS code J7318 and Medicare coverage under Local Coverage Determination L39260 for eligible knee OA patients [3], reducing the administrative barrier to adoption in billing-sensitive practices.

About DUROLANE® — Single-Injection Viscosupplementation for Knee and Ankle

DUROLANE® is a single-injection hyaluronic acid viscosupplement developed using proprietary NASHA technology. Originally developed by Q-Med AB in Sweden, it received FDA Premarket Approval (PMA P170007) in 2017 following clinical trials that demonstrated non-inferiority to a five-injection hyaluronic acid regimen [2]. It is now marketed by Bioventus in multiple regions; practitioners should confirm the current marketing authorization holder in the IFU for their applicable market.

Its NASHA structure forms a stabilized gel that persists longer in the joint than non-cross-linked hyaluronic acid preparations, allowing the full therapeutic dose to be delivered in a single visit rather than a multi-injection course [1]. Indications vary by market; in the US, DUROLANE® is indicated for knee osteoarthritis, while non-US labeling may include additional joints depending on the applicable regional IFU [2][3]. Practitioners considering DUROLANE® injections for knees or other joints should confirm the applicable approved indication for their market before procurement.

About the Manufacturer

DUROLANE® was originally developed by Q-Med AB, a Swedish company specializing in hyaluronic acid-based medical products, and the NASHA platform has an extensive history of clinical validation spanning both viscosupplementation and aesthetic medicine [1]. DUROLANE® is now marketed by Bioventus in multiple regions; practitioners should verify the current manufacturer and marketing authorization holder from the most recent IFU applicable to their market, as product ownership has changed over time [3].

Bioventus’ orthopedic portfolio includes both single-injection and multi-injection viscosupplement options, giving practitioners access to a range of hyaluronic acid injection formats within a single supplier relationship [3].

DUROLANE® Technology — NASHA and Joint Lubrication

DUROLANE® is a gel preparation that replenishes joint fluid to restore lubrication and reduce pain associated with osteoarthritis. As osteoarthritis progresses, the natural hyaluronic acid in the joint declines in concentration and quality, reducing its ability to lubricate and cushion the joint during movement [1]. DUROLANE® addresses this by delivering a high-concentration, high-molecular-weight NASHA gel directly into the intra-articular space.

The NASHA process produces hyaluronic acid through bacterial biofermentation, making it non-avian and suitable for patients with avian protein hypersensitivity [1][3]. Its NASHA structure forms a stabilized gel that persists longer in the joint than non-cross-linked hyaluronic acid preparations [1]. Bioventus describes DUROLANE® as having the highest reported molecular weight of any HA product approved in the US [5], and the stabilized gel matrix supports delivery of the full therapeutic dose in a single injection.

DUROLANE® is not a corticosteroid. It contains only stabilized hyaluronic acid and works by lubricating and restoring the viscoelastic properties of synovial fluid — a mechanism entirely distinct from that of intra-articular steroid injections [1][3]. Practitioners seeking related HA-based products for aesthetic applications can buy HA dermal fillers or buy dermal fillers across the Medical Spa Rx catalog, where NASHA technology also underpins several leading filler brands.

DUROLANE® Product Spotlight

DUROLANE® 60 mg/3 mL is supplied as a sterile, ready-to-use prefilled glass syringe delivering 60 mg of NASHA-stabilized sodium hyaluronate in 3 mL (20 mg/mL). Each syringe is intended for single intra-articular use only and delivers the full therapeutic dose in a single injection, eliminating the need for repeat treatment visits [3].

Per current prescribing information, DUROLANE® should be stored at or below 25°C and must not be frozen [3]. Syringes should be inspected before use and discarded if damaged, discolored, or expired. Each unit is single-use only and must not be re-sterilized or reused [3]. Practitioners should verify the current NDC number using the latest prescribing information or manufacturer resources before procurement, as product codes are subject to change and outdated numbers can cause claim-processing errors.

Licensed practitioners can buy DUROLANE® wholesale through Medical Spa Rx, with bulk ordering available alongside individual-unit purchasing for practices that manage variable injection volumes. Practitioners stocking multiple viscosupplement options can also buy orthopedic injections across the full Medical Spa Rx catalog.

Treatment Areas and Patient Indications

DUROLANE® is indicated for adults with osteoarthritis who have not achieved adequate relief from conservative treatment and is frequently used as a non-surgical option before joint replacement is considered. Indications vary by country: in the United States, the FDA-approved indication covers knee osteoarthritis following an inadequate response to conservative therapy or simple analgesics [2][3]. Non-US labeling may include additional joint indications depending on the applicable market; published clinical evidence also documents use in joints beyond the knee in some markets, and practitioners should confirm the indication applicable to their jurisdiction before administering DUROLANE® for any joint [4].

Suitable candidates are adults with symptomatic osteoarthritis confirmed clinically and radiographically who continue to experience pain and reduced mobility despite physical therapy, exercise, weight management, or analgesics, and who prefer to complete treatment in a single clinic visit. DUROLANE® is contraindicated in patients with hypersensitivity to sodium hyaluronate, active joint infections, or skin disease or infection at or near the injection site [3]. It has not been evaluated in pregnant or breastfeeding women or in pediatric patients, and is therefore not recommended for these populations [3]. Practitioners should review the prescribing information for each product and confirm the applicable indications for their market before administering the product.

Administration and Recovery

DUROLANE® is administered as a single intra-articular injection, allowing treatment to be completed in one clinic visit. The full 3 mL dose is delivered using strict aseptic technique [3]. If joint effusion is present, excess fluid should be aspirated before injection to improve comfort and optimize product distribution within the joint [3]. Accurate needle placement should be confirmed using anatomical landmarks or imaging guidance — ultrasound or fluoroscopy is particularly recommended for joints that are more difficult to access, in order to guide the needle precisely into the intra-articular space [4].

Recovery is generally straightforward. Most patients can walk immediately after the procedure, with a recommended restriction on strenuous or high-impact activities for approximately 24 to 48 hours [3]. Some patients begin to notice improvement within a few days to two weeks of treatment, and clinical evidence supports pain relief lasting up to 26 weeks in some patients following a single DUROLANE® injection [1].

Regulatory Status and Billing

DUROLANE® received FDA Premarket Approval (PMA P170007) in 2017 for the treatment of knee osteoarthritis pain, following trials demonstrating non-inferiority to a five-injection hyaluronic acid regimen [2]. It is regulated as a Class III medical device under FDA oversight. Practitioners wishing to purchase DUROLANE® should confirm that the applicable regulatory status is in place for their jurisdiction before procurement.

For billing, the current HCPCS code is J7318 — hyaluronan or derivative, DUROLANE®, for intra-articular injection, per 1 mg — and the standard CPT procedure code for major joint intra-articular injection is CPT 20610. DUROLANE® is included among viscosupplements covered under Medicare Part B Local Coverage Determination L39260 for eligible knee OA patients, with coverage generally requiring documented OA, inadequate response to conservative therapies, and administration per approved prescribing information [3]. Private insurance coverage varies by carrier and may require prior authorization or step therapy. Because CMS periodically updates billing guidance, practitioners should verify current HCPCS and CPT codes with their billing team or the applicable Medicare Administrative Contractor before submitting claims. The DUROLANE® NDC number is product-specific and subject to change; confirm the current NDC from the latest prescribing information or manufacturer documentation before ordering.

DUROLANE® Safety Profile — Side Effects and Contraindications

Common adverse events with DUROLANE® include localized pain, swelling, warmth, and arthralgia at the injection site; these are generally self-limiting and resolve within a few days of treatment [2][3]. As with any intra-articular injection, there is a small risk of infection and hemarthrosis, which can be minimized through proper aseptic technique and appropriate patient selection [2].

DUROLANE® is contraindicated in patients with known hypersensitivity to sodium hyaluronate or any product component, active joint infection, and skin disease or infection at or near the injection site [3]. The risks associated with DUROLANE® injections in pregnant or breastfeeding women and in pediatric patients have not been evaluated; use in these populations is not recommended [3]. Practitioners should review the full prescribing information for complete data on contraindications and precautions before treatment.

Comparing DUROLANE® to Other Viscosupplements

DUROLANE® vs MONOVISC®

Both DUROLANE® and MONOVISC® are non-avian, single-injection viscosupplements produced through bacterial fermentation, making both suitable for patients with avian protein hypersensitivity. DUROLANE® uses the NASHA-stabilized gel format at 60 mg/3 mL, while MONOVISC® delivers a different cross-linked hyaluronan formulation at 88 mg/4 mL [4]. Practitioners comparing single-injection non-avian options for knee osteoarthritis can buy MONOVISC® alongside DUROLANE® to compare formulations and volumes.

DUROLANE® vs SYNVISC®

DUROLANE® and Synvisc-One® both provide viscosupplementation in a single injection, but differ substantially in their formulation sources and molecular architectures. DUROLANE® contains NASHA-stabilized, biofermentation-derived, high-molecular-weight hyaluronic acid, while Synvisc-One® contains avian-derived hylan G-F 20 [1][4]. DUROLANE® has no contraindication for avian protein hypersensitivity; Synvisc-One® does. Practitioners evaluating these two single-visit options can buy SYNVISC® to compare formulation profiles and patient suitability criteria.

DUROLANE® vs ORTHOVISC®

ORTHOVISC® is a non-avian, non-cross-linked sodium hyaluronate administered over three to four weekly injections. DUROLANE® provides the same indication in a single injection using NASHA-stabilized hyaluronic acid and may be preferred when reducing the total number of clinic visits is a treatment priority [4]. Both products are non-avian and suitable for patients with avian protein hypersensitivity. Practitioners can buy ORTHOVISC® when a multi-injection non-avian protocol is clinically appropriate.

DUROLANE® vs EUFLEXXA®

EUFLEXXA® is a non-avian, non-cross-linked sodium hyaluronate administered as three weekly injections. Like DUROLANE®, it is produced through biofermentation and is suitable for patients with avian protein hypersensitivity, but requires a three-visit treatment schedule compared with DUROLANE®’s single-injection format [4]. Practitioners can buy EUFLEXXA® when a multi-injection non-avian viscosupplement is the preferred clinical approach.

DUROLANE® vs HYALGAN®

HYALGAN® is an avian-derived, non-cross-linked sodium hyaluronate administered across a five-week injection series. Compared with DUROLANE®, it differs in source material, molecular structure, and treatment schedule, and is not suitable for patients with avian protein hypersensitivity [4]. Practitioners may buy HYALGAN® when a multi-injection avian-derived regimen is indicated, and patient hypersensitivity is not a concern.

DUROLANE® vs SUPARTZ®

SUPARTZ® is an avian-derived, non-cross-linked sodium hyaluronate administered over three to five weekly injections. DUROLANE® is non-avian, uses NASHA stabilization, and completes treatment in a single injection [4]. Although both products are available through Bioventus’ portfolio, they serve different patient profiles and treatment schedules. Practitioners can buy SUPARTZ® when an avian-derived multi-dose viscosupplement is appropriate for the patient’s clinical profile.

FAQs

What is DUROLANE®?

DUROLANE® is a single-injection NASHA hyaluronic acid viscosupplement — 60 mg in 3 mL — indicated in the United States for knee osteoarthritis pain in patients who have not responded adequately to conservative therapy or simple analgesics [2][3]. Its NASHA gel is produced via bacterial biofermentation and forms a high-molecular-weight, stabilized structure that persists longer in the joint than non-cross-linked HA preparations [1].

Is DUROLANE® approved for ankle osteoarthritis?

In the United States, FDA approval is limited to knee osteoarthritis only [2]. Non-US labeling may include additional joint indications depending on the applicable market, and published clinical data document use of hyaluronic acid viscosupplementation in joints beyond the knee in some markets [4]. Practitioners should confirm the approved indication in their jurisdiction before administering DUROLANE® for any joint other than the knee.

Is DUROLANE® a steroid?

No. DUROLANE® is a hyaluronic acid medical device, not a corticosteroid. It contains no steroid components and works by supplementing intra-articular hyaluronic acid to assist in lubrication and restore the viscoelastic properties of synovial fluid — a mechanism entirely distinct from intra-articular steroid injections [1][3].

How does DUROLANE® work?

DUROLANE® replenishes hyaluronic acid in the osteoarthritic joint by delivering a high-dose NASHA gel directly into the intra-articular space. Its stabilized gel structure is designed to persist longer in the joint than non-cross-linked preparations, assisting in lubrication and shock absorption during movement [1]. Evidence also suggests it may support ongoing production of new hyaluronic acid by synovial tissue, contributing to sustained lubrication beyond the mechanical effect of the injected dose [1].

Can you walk after a DUROLANE® injection?

Yes — most patients are able to walk immediately following the procedure. A brief restriction on strenuous or high-impact activities is recommended for approximately 24 to 48 hours, after which normal activity can be resumed progressively based on comfort and clinical response [3].

How long does it take for DUROLANE® injection to work?

Some patients begin to notice improvement within a few days to two weeks of treatment [1]. Full benefit develops progressively over subsequent weeks, with clinical evidence supporting pain relief lasting up to 26 weeks in some patients following a single injection [1]. Individual results vary based on disease severity and patient factors.

What is the DUROLANE® J code?

The current HCPCS billing code for DUROLANE® is J7318 (hyaluronan or derivative, DUROLANE®, for intra-articular injection, 1 mg), and the standard CPT code for intra-articular injection of a major joint is CPT 20610 [3]. Practitioners should verify current codes with their billing team or the applicable Medicare Administrative Contractor before submitting claims, as CMS guidance is updated periodically.

DUROLANE® vs SYNVISC® — how do they compare?

Both are single-injection viscosupplements, but DUROLANE® uses NASHA-stabilized, non-avian, biofermentation-derived hyaluronic acid, while Synvisc-One® uses avian-derived, cross-linked hylan G-F 20 [1][4]. DUROLANE® has no contraindication for avian protein hypersensitivity; Synvisc-One® does. The comparison is most relevant to patient contraindication profiles and formulation preferences.

Trying to buy DUROLANE® injection online?

Medical Spa Rx offers DUROLANE® with secure checkout, add-to-cart ordering, and both individual and bulk purchasing options for licensed practitioners. You can buy DUROLANE® injection online, compare it against other viscosupplement options in the orthopedic catalog, and place wholesale orders to suit your practice’s stocking requirements. Browse the product above and proceed to secure checkout — or contact Medical Spa Rx directly for bulk pricing inquiries.

Resources

1. Leighton R, Fitzpatrick J, Smith H, Crandall D, Flannery CR, Conrozier T. Systematic clinical evidence review of NASHA (Durolane hyaluronic acid) for the treatment of knee osteoarthritis. Open Access Rheumatology: Research and Reviews. 2018;10:43–54.https://pubmed.ncbi.nlm.nih.gov/29849470/
2. S. Food and Drug Administration. Summary of safety and effectiveness data (SSED) — DUROLANE, PMA P170007. FDA Medical Device Database. 2017. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170007B.pdf
3. Bioventus LLC. DUROLANE (sodium hyaluronate) instructions for use. 2017. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170007D.pdf
4. Webner D, Huang Y, Hummer CD 3rd. Intraarticular Hyaluronic Acid Preparations for Knee Osteoarthritis: Are Some Better Than Others?. Cartilage. 2021;13(1 Suppl):937S–959S. https://pmc.ncbi.nlm.nih.gov/articles/PMC8808930/
5. DUROLANE proven innovation. Bioventus OA Knee Pain Relief. https://www.oakneepainrelief.com/durolane/proven-innovation/

The page and all of its displayed contents are for medical professionals, designed to inform only, and not as a replacement for medical advice.